At InterVenn Biosciences, we’ve developed a platform to unlock the glycoproteome, thereby enabling novel insights into disease biology. With access to this hidden layer of biology, we have the opportunity to uncover novel solutions to previously unsolvable problems, leading to breakthrough discoveries in precision medicine.
Interested in joining our mission as an investor?
InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
Business Wire | October 13, 2023
Read MoreInterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
Business Wire | September 27, 2023
Read MoreInterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023
Business Wire | April 19, 2023
Read More